Cargando…

The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis

OBJECTIVE: To assess the association between the use of biological disease-modifying antirheumatic drugs (bDMARDs) and the risk of cardiovascular events in patients with systemic inflammatory conditions. METHODS: Eligible cohort studies or randomized controlled trials (RCTs) from inception to Januar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Suiyuan, Lin, Chu, Cai, Xiaoling, Zhu, Xingyun, Lv, Fang, Nie, Lin, Ji, Linong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423578/ https://www.ncbi.nlm.nih.gov/pubmed/34504395 http://dx.doi.org/10.1155/2021/7712587

Ejemplares similares

The Urinary Glucose Excretion by Sodium–Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2022)

Disparities in efficacy and safety of sodium-glucose cotransporter 2 inhibitor among patients with different extents of renal dysfunction: A systematic review and meta-analysis of randomized controlled trials
por: Hu, Suiyuan, et al.
Publicado: (2022)

The Effect of Physical Activity on Glycemic Variability in Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Zhu, Xingyun, et al.
Publicado: (2021)

Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials
por: Yang, Wenjia, et al.
Publicado: (2022)

SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
por: Lin, Chu, et al.
Publicado: (2021)

Correction to: SGLT2 inhibitors and lower limb complications: an updated meta-analysis
por: Lin, Chu, et al.
Publicado: (2021)

Trends in baseline HbA1c and body-mass index in randomised placebo-controlled trials of type 2 diabetes from 1987 to 2022: a systematic review and meta-analysis
por: Hu, Suiyuan, et al.
Publicado: (2023)

The Body Weight Alteration and Incidence of Neoplasm in Patients With Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
por: Lin, Chu, et al.
Publicado: (2020)

Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus
por: Lin, Chu, et al.
Publicado: (2020)

Are biologics more effective than classical disease-modifying antirheumatic drugs?
por: Nurmohamed, Michael T, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy
por: Czekalska, Anna, et al.
Publicado: (2019)

Estimation of atherosclerotic cardiovascular disease risk in type 2 diabetes
por: Cai, Xiaoling, et al.
Publicado: (2022)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
por: Kaló, Zoltán, et al.
Publicado: (2017)

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation
por: Góralczyk, Alicja, et al.
Publicado: (2020)

Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
por: Abdul Razak, Salmi, et al.
Publicado: (2020)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Non-Insulin Antidiabetes Treatment in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Cai, Xiaoling, et al.
Publicado: (2021)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine
por: Daïen, Claire I., et al.
Publicado: (2014)

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
por: Sullivan, Emma, et al.
Publicado: (2020)

Evaluation of Access Disparities to Biologic Disease-Modifying Antirheumatic Drugs in Rural and Urban Communities
por: Peterman, Nicholas J, et al.
Publicado: (2022)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

Hypersensitivity reactions to biologic disease modifying antirheumatic drugs: experience from the TTSH Singapore biologics registry
por: Thong, Bernard, et al.
Publicado: (2014)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
por: Baker, Matthew C., et al.
Publicado: (2023)

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
por: Song, Yun-Kyoung, et al.
Publicado: (2023)

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
por: Wang, Szu-Hsuan, et al.
Publicado: (2022)

Comparison of the Effect of Disease: Modifying Antirheumatic Drugs Alone or in Combination with Biologic Drugs in the Outcome of Patients with Rheumatoid Arthritis
por: Mousavi, Maryam, et al.
Publicado: (2019)

Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis
por: Kim, Se Hee, et al.
Publicado: (2021)

The association between metabolic parameters and evening chronotype and social jetlag in non-shift workers: A meta-analysis
por: Zhang, Rui, et al.
Publicado: (2022)

The association between age and adverse events due to biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A retrospective cohort study
por: Ikari, Yuzo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7m9hbthiuikqdhbjv3kso5c35q